Project Details
Description
Neovascular age related macular degeneration (nAMD) is a leading cause of blind
registrations in the developed world. Although the overall clinical efficacy of anti-VEGF therapy in nAMD is clear, significant variation in the visual acuity outcomes of treated Neovascular Age-related macular degeneration (nvAMD) have been documented in the UK and internationally.
The purpose of this study is to summarise the demographic and clinical factors that influence the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in patients with nAMD, in settings comparable to the National Health Service (NHS).
The Studentship is funded by Bayer PLC (via York Teaching Hospitals NHS Foundation Trust)
registrations in the developed world. Although the overall clinical efficacy of anti-VEGF therapy in nAMD is clear, significant variation in the visual acuity outcomes of treated Neovascular Age-related macular degeneration (nvAMD) have been documented in the UK and internationally.
The purpose of this study is to summarise the demographic and clinical factors that influence the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in patients with nAMD, in settings comparable to the National Health Service (NHS).
The Studentship is funded by Bayer PLC (via York Teaching Hospitals NHS Foundation Trust)
| Short title | The FASBAT Study |
|---|---|
| Status | Finished |
| Effective start/end date | 1/10/17 → 30/09/20 |